Showing papers in "Journal of Hepatology in 2017"

TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

TL;DR: These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.

TL;DR: Clinical evidence strongly supports the role of lifestyle modification as a primary therapy for the management of NAFLD and NASH and should be accompanied by the implementation of strategies to avoid relapse and weight regain.

TL;DR: The epidemiological trend of obesity in Asia is reviewed, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD), and pharmacological agents have entered phase III development for steatohepatitis.

TL;DR: In this, the largest ever study of biopsy-proven NAFLD, the presence of NASH did not increase the risk of liver-specific morbidity or overall mortality.

TL;DR: It is shown that cholesterol crystals could be one pathway to activate the inflammasome in NASH, and a drug called MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice.

TL;DR: CAP provides a standardized non-invasive measure of hepatic steatosis and factors such as the underlying disease, BMI and diabetes must be taken into account when interpreting CAP.

TL;DR: Evidence from mouse models and early clinical studies in patients with non-alcoholic steatohepatitis and fibrosis support the notion that pathogenic macrophage subsets can be successfully translated into novel treatment options for patients with liver disease.

TL;DR: Tremelimumab in combination with tumor ablation is a potential new treatment for patients with advanced HCC, and leads to the accumulation of intratumoral CD8+ T cells, with a possible surrogate reduction in HCV viral load.

TL;DR: This review provides an overview of the strategies available for a specific targeting of LSECs and presents a detailed analysis of the technical aspects relevant for LSEC analysis including the markers these cells express, the available cell lines and the transgenic mouse models.

TL;DR: The term acute liver failure (ALF) is frequently applied as a generic expression to describe patients presenting with or developing an acute episode of liver dysfunction, however, it refers to a highly specific and rare syndrome, characterised by an acute abnormality of liver blood tests in an individual without underlying chronic liver disease.

TL;DR: Control of hepatitis B (HBV) and hepatitis C virus (HCV) infections has contributed to the decrease in HCC-related mortality in East Asia and Southern Europe, and predicted trends for some countries to 2020.

TL;DR: A comprehensive review of the status of the PSC field is provided, emphasise developments related to patient stratification and disease behaviour, and provides an overview of management options from a practical, patient-centered perspective.

TL;DR: It is shown here that HCC phenotype is tightly associated to its molecular alterations and underlying oncogenic pathways, both at the pathological and molecular levels.

TL;DR: Treatment with sorafenib provides a survival benefit in all subgroups of patients with HCC; however, the magnitude of benefit is greater in patients with disease confined to the liver (without extrahepatic spread), or in those with hepatitis C virus, or a lower neutrophil-to-lymphocyte ratio, an indicator of inflammation status.

TL;DR: A meta-analysis to compare occurrence and recurrence of HCC in patients receiving either DAA or interferon (IFN) therapy found there is no evidence that HCC occurrence or recurrence is different between patients receiving DAA and IFN therapy.

TL;DR: Development of standardised assays for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with development of novel antiviral and immune modulatory therapies such that approval of new treatments can be linked to the approval ofnew diagnostic assays used to measure efficacy or to predict response.

TL;DR: Low muscle mass was found to be associated with histological severity in non-alcoholic fatty liver disease, and sarcopenia was significantly associated with non- alcoholic steatohepatitis and significant fibrosis, independent of obesity, inflammation, and insulin resistance.

TL;DR: Examples of the functions of ncRNAs in liver cancer and their potential use for the detection and treatment of liver cancer are reviewed.

TL;DR: The gut-liver axis is widely implicated in the pathogenesis of liver diseases, where it is increasingly the focus of clinical research and an exciting future in liver treatment is promised.

TL;DR: Resistance exercise may be more feasible than aerobic exercise for NAFLD patients with poor cardiorespiratory fitness or for those who cannot tolerate or participate in aerobic exercise.

TL;DR: The ongoing controversy surrounding the proper role for this ubiquitous pain reliever is reviewed: its history, pathogenesis, clinical challenges in recognition and management, and current regulatory status are highlighted.

TL;DR: The mechanisms of acetaminophen-induced liver injury in mice and man are discussed with a particular focus on the role of inflammation and the inflammasome.

TL;DR: Percutaneous ablation could also be used as a bridge to liver transplantation or in a sequence of upfront percutaneous treatment, followed by transplantation if the patient relapses, and several innovations in ablation methods may help to efficiently treat early HCC.

TL;DR: A combination of two or more of the following; arterial per itumoral enhancement, non-smooth tumor margin, and peritumoral hypointensity on hepatobiliary phase, can be used as a preoperative imaging biomarker for predicting MVI, with specificity >90%, and is associated with early recurrence after surgery of single HCC.

TL;DR: With newer data on combination treatment of PegIFN and nucleos(t)ide analogues as well as emerging new antiviral agents, HBsAg quantification is expected to become increasingly important to monitor and guide antiviral therapy for chronic hepatitis B.

TL;DR: Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations.

TL;DR: LT strongly influences the survival of patients with cirrhosis and ACLF-3 with a 1-year survival similar to that of Patients with a lower grade of ACLF, suggesting that patients with ACLf-3 should be rapidly referred to a specific liver ICU.

TL;DR: Evidence is provided that AFP-enriched DEXs can trigger potent antigen-specific antitumor immune responses and reshape the tumor microenvironment in HCC mice and thus provide a cell-free vaccine option for HCC immunotherapy.